Since it was founded in 2012, the CDCN has harnessed the power of its global network of physicians and researchers to relentlessly pursue a cure for Castleman disease. The CDCN has funded or supported over 40 high-impact studies that have led to breakthroughs including the first-ever diagnostic criteria, the first-ever treatment guidelines, the discovery of a novel treatment target for iMCD (mTOR pathway) and sirolimus as a new treatment, and more. Physicians & researchers can join the CDCN’s physician & researcher community to gain access to all resources in this section.
Learn about the latest in CD Research:
-
- Lists and explains all current CDCN research projects with a description and a corresponding status.
-
- A clinical trial is open in the USA to investigate sirolimus for iMCD patients who did not respond to anti-IL-6 therapy (siltuximab) at the University of Pennsylvania and the University of Arkansas for Medical Sciences
-
- Continuously updated resources including full-print versions of recent CD publications, the CD UpToDate pages, and our pathology toolkit.
-
-
The CDCN underwent a crowdsourcing effort in 2013 to determine the key research questions that need to be answered to achieve the CDCN’s vision of a world where CD patients’ lives are not limited in length or quality by CD. The below overarching research questions were identified as well as a number of specific research questions that have been investigated over the last 8 years. See below for updates and keep an eye our for the results of the All In Movement AIM 2021.
-
-
- The first-ever iMCD treatment guidelines were published in the journal Blood in 2018. Please visit here for more information.
-
- The Center for Study & Treatment of Castleman & Inflammatory Lymphadenopathies (CSTL) was started by CDCN Co-Founder Dr. Fagjenbaum at the Perelman School of Medicine at the University of Pennsylvania
-
- Join CDCN Connect, a private virtual community for connecting with one another and advancing a cure. CDCN Connect allows physicians and researchers to participate in physician-to-physician case discussions, share research findings, and contribute research ideas. You must be registered as a physician or researcher with the CDCN to join CDCN Connect.
-
- Log in or create an account to access all password-protected resources on our website.